SVRA

Savara, Inc.

4.18 USD

Last updated Dec 9, 17:41 UTC

Yesterday HIGH

$4.27

Yesterday LOW

$3.98

52w HIGH

$4.27

52w LOW

$1.42

EPS

-0.1

PE

-41.80

Next Earnings

Mar 28, 2024

Overview News Government Trades

Savara, Inc. stock is up 22.58% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 December’s closed higher than November. 100% of analysts rate it a buy.

Savara Inc. focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor. The company is headquartered in Austin, Texas.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Wilmington, United States Of America

Website

savarapharma.com

richadhand@benzinga.com

Wed May 17, 2023

HC Wainwright & Co. Reiterates Buy on Savara, Maintains $3 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Savara (NASDAQ:SVRA) with a Buy and maintains $3 price target.
Benzinga Newsdesk

Mon May 15, 2023

Savara Q1 EPS $(0.07) Down From $(0.05) YoY; Cash And Cash Equivalents Of $114.8M

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.07) per share. This is a 40 percent decrease over losses of $(0.05) per share from the same period last year. As of March 31, 2023, the Company had cash, cash
richadhand@benzinga.com

Tue Apr 4, 2023

HC Wainwright & Co. Reiterates Buy on Savara, Maintains $3 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Savara (NASDAQ:SVRA) with a Buy and maintains $3 price target.
Benzinga Insights

Mon Apr 3, 2023

Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
richadhand@benzinga.com

Mon Apr 3, 2023

Jefferies Downgrades Savara to Hold, Announces $2 Price Target

Jefferies analyst Suji Jeong downgrades Savara (NASDAQ:SVRA) from Buy to Hold and announces $2 price target.
Happy Mohamed

Thu Mar 30, 2023

Savara Q4 EPS $(0.07), Inline

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Lisa Levin

Tue Feb 21, 2023

JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Benzinga Newsdesk

Tue Feb 14, 2023

Savara Names Rob Lutz As COO, Effectively Immediately
Lisa Levin

Wed Jan 4, 2023

$1.2 Million Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying

The Dow Jones edged lower on the first trading session of 2023. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga Newsdesk

Thu Nov 10, 2022

Savara Q3 EPS $(0.07), Same YoY

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.07) per share. This is unchanged from the same period last year.